Ixico PLC - London-based neuroscience data analytics company - Says it has extended a contract originally signed in April 2019. The existing client will use Ixico's services on its phase I/II trial into Huntington's disease. The contract extension is worth around GBP800,000, which Ixico expects to deliver across a four-year period.
Current stock price: 36.50 pence, down 2.7% in London on Tuesday
12-month change: down 57%
By Sophie Rose; sophierose@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Ixico (IXI)